Skip to main content

Advertisement

Log in

Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)

  • Letter to the Editor
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F (2013) Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 98:1361–1375

    Article  PubMed  CAS  Google Scholar 

  2. Torino F, Barnabei A, De Vecchis L, Salvatori R, Corsello SM (2012) Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist 17:525–535

    Article  PubMed  Google Scholar 

  3. Weber JS, Kähler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:2691–2697

    Article  PubMed  CAS  Google Scholar 

  4. Yervoy (ipilimumab): serious and fatal immune-mediated adverse reactions. www.yervoy.com/hcp/rems

  5. Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA, Sherry RM (2005) Cytotoxic T-lymphocyte associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28:593–598

    Article  PubMed  CAS  Google Scholar 

  6. Juszczak A, Gupta A, Karavitaki N, Middleton MR, Grossman AB (2012) Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol 167:1–5

    Article  PubMed  CAS  Google Scholar 

  7. Min L, Vaidya A, Becker C (2012) Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. Endocr Pract 18:351–355

    Article  PubMed  Google Scholar 

  8. Carpenter KJ, Murtagh RD, Lilienfeld H, Weber J, Murtagh FR (2009) Ipilimumab-induced hypophysitis: MR imaging findings. AJNR Am J Neuroradiol 30:1751–1753

    Article  PubMed  CAS  Google Scholar 

  9. Hamnvik OP, Larsen PR, Marqusee E (2011) Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst 103:1572–1587

    Article  PubMed  CAS  Google Scholar 

  10. Min L, Vaidya A, Becker C (2011) Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 164:303–307

    Article  PubMed  CAS  Google Scholar 

  11. Borodic G, Hinkle DM, Cia Y (2011) Drug-induced Graves’ disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg 27:e87–e88

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Salvatore Maria Corsello.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Corsello, S.M., Salvatori, R., Barnabei, A. et al. Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not). Cancer Chemother Pharmacol 72, 489–490 (2013). https://doi.org/10.1007/s00280-013-2213-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-013-2213-y

Keywords

Navigation